Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Addresses Serzone/Seroquel Mix-Ups With Patient Information Leaflet

Executive Summary

Bristol-Myers Squibb will distribute Serzone patient information leaflets with each prescription of the anti-depressant, to address medication mix-ups with AstraZeneca's anti-psychotic Seroquel

You may also be interested in...



Color-Coded Rx Packaging Could Reduce Errors; Method Requires Study

Color-coded drug packaging and labeling could help reduce medication errors in certain circumstances, but the method requires testing prior to adoption, participants at a March 7 FDA public hearing said

Color-Coded Rx Packaging Could Reduce Errors; Method Requires Study

Color-coded drug packaging and labeling could help reduce medication errors in certain circumstances, but the method requires testing prior to adoption, participants at a March 7 FDA public hearing said

Bristol Serzone Status Unchanged In U.S.; Antidepressant Pulled In Europe

FDA is comfortable with Serzone's current labeling, the agency said following Bristol-Myers Squibb's decision to pull the antidepressant off the market in Europe

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel